[go: up one dir, main page]

AR065034A1 - Metodos para prevenir y tratar trastornos neurodegenerativos - Google Patents

Metodos para prevenir y tratar trastornos neurodegenerativos

Info

Publication number
AR065034A1
AR065034A1 ARP080100311A ARP080100311A AR065034A1 AR 065034 A1 AR065034 A1 AR 065034A1 AR P080100311 A ARP080100311 A AR P080100311A AR P080100311 A ARP080100311 A AR P080100311A AR 065034 A1 AR065034 A1 AR 065034A1
Authority
AR
Argentina
Prior art keywords
prevent
methods
neurodegenerative disorders
treat neurodegenerative
patient
Prior art date
Application number
ARP080100311A
Other languages
English (en)
Inventor
Weitesrstadt Wienrich
Jurgen Reess
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065034(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR065034A1 publication Critical patent/AR065034A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar, prevenir o ralentizar, retrasar o invertir el avance dc uno o mas trastornos neurodegencrativos en un paciente que lo necesite, caracterizado por la administracion de un derivado de benceno sustituido con glucopiranosilo, uno de sus tautomeros, estercoisorneros, mezcIas o sales, corno se define en la reivindicacion 1, al paciente que lo necesita.
ARP080100311A 2007-01-26 2008-01-25 Metodos para prevenir y tratar trastornos neurodegenerativos AR065034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101213 2007-01-26

Publications (1)

Publication Number Publication Date
AR065034A1 true AR065034A1 (es) 2009-05-13

Family

ID=39315016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100311A AR065034A1 (es) 2007-01-26 2008-01-25 Metodos para prevenir y tratar trastornos neurodegenerativos

Country Status (4)

Country Link
AR (1) AR065034A1 (es)
CL (1) CL2008000223A1 (es)
TW (1) TW200843785A (es)
WO (1) WO2008090209A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
EP1660509B1 (de) * 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004058449A1 (de) * 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
WO2006127842A2 (en) * 2005-05-23 2006-11-30 The Regents Of The University Of California Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido

Also Published As

Publication number Publication date
WO2008090209A2 (en) 2008-07-31
WO2008090209A3 (en) 2008-10-02
TW200843785A (en) 2008-11-16
CL2008000223A1 (es) 2008-05-23

Similar Documents

Publication Publication Date Title
AR065034A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
MX2011011958A (es) Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
CL2011002185A1 (es) Compuestos n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)-carbamoil)benzofuran-4-iloxi)pirimidin-2-carboxamida y sus sales; composicion farmaceutica que los comprende; y su uso como activadores de la glucoquinasa para tratar la obesidad y para tratar o retrasar la progresion o el comienzo de la diabetes de tipo 2 y trastornos relacionados.
CR20110103A (es) Heteroarilos sustituidos
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
GT200900315A (es) Inhibición de arni de expresión de alfa-enac
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CL2008002826A1 (es) Compuestos derivados de pirimidina alquiltio sustituidas, antagonista crth2; composicion farmaceutica que comprende a dicho compuestos; y uso para tratar una enfermedad alergica, asma, dermatitis atopica, psoriasis, colitis ulcerantes, sinusitis, leucemia basofilica, entre otras.
DOP2010000321A (es) Derivados de iminopirimidina y su uso
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure